Investment Rating - The investment rating for the company is "Buy" [8] Core Insights - The company reported a revenue of 1.515 billion yuan in 2024, representing a year-on-year increase of 28.38%, and a net profit attributable to shareholders of 548 million yuan, up 33.08% year-on-year [1] - The company has a high dividend payout ratio of over 80% for 2024, with an expected dividend yield of 5.7% for 2025 [4] - The railway investment in 2025 is expected to remain high, with a total fixed asset investment of 850.6 billion yuan in 2024, an increase of 11.26% year-on-year [3] Revenue Breakdown - The revenue from the train control system reached 886 million yuan in 2024, a growth of 25.89% year-on-year [2] - The railway security segment generated 238 million yuan in revenue, up 25.64% year-on-year [2] - The high-speed rail operation monitoring segment saw a revenue increase of 39.79%, totaling 358 million yuan [2] Financial Forecasts - The company is projected to achieve net profits of 680 million yuan, 830 million yuan, and 980 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 24%, 22%, and 18% [5] - The expected price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are 14, 12, and 10 respectively [5] Dividend Policy - The company plans to distribute a cash dividend of 11.8828 yuan per 10 shares for 2024, totaling 453 million yuan, which is approximately 83% of the net profit attributable to shareholders [4] - The company aims to maintain a dividend payout ratio of 80% during its mature development phase without significant capital expenditures [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's main business in baby pants has stabilized and is showing signs of recovery, while the acquisition of the Jieting brand is expected to drive growth [5] - The company reported a revenue of 2.93 billion yuan for 2024, a year-on-year increase of 6.3%, but a net profit of 390 million yuan, a decrease of 11.7% year-on-year [1][11] - The company continues to provide high dividend returns to shareholders, proposing a cash dividend of 8.5 yuan per 10 shares and a capital reserve transfer of 4 shares for every 10 shares [1] Revenue Breakdown - Baby hygiene products generated 2.06 billion yuan in revenue for 2024, up 4.3% year-on-year, with a sales volume of 3.04 billion pieces, an increase of 12.3% [2] - Adult hygiene products saw revenue of 550 million yuan, a slight decrease of 0.6% year-on-year, while other products experienced significant growth with a revenue of 230 million yuan, up 57.6% [2] - Domestic revenue in the second half of 2024 was 1.27 billion yuan, up 6.3% year-on-year, while overseas revenue reached 260 million yuan, a substantial increase of 67.2% [2] Profitability Analysis - The company's gross margin for 2024 was 27.91%, an increase of 0.97% year-on-year, primarily due to reduced material costs from increased in-house production [3] - The net profit margin for 2024 was 13.2%, down 2.7 percentage points year-on-year, with a significant decline in the fourth quarter [3] - Sales expenses increased significantly due to enhanced marketing for the company's own brands, with online promotion costs rising by 88.5% year-on-year [4] Future Outlook - The acquisition of Hubei Sibao Care is expected to significantly enhance the company's performance, with Sibao achieving a revenue of 680 million yuan in 2024, up 26% year-on-year [5] - The company is expanding production capacity and has acquired production lines from major brands to improve its market share [5] - Revenue projections for 2025-2027 are 3.74 billion, 4.20 billion, and 4.66 billion yuan, respectively, with corresponding net profits of 486 million, 547 million, and 617 million yuan [11]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [8] Core Views - The company achieved a revenue of 1.078 billion yuan in 2024, representing a year-on-year increase of 15.7%, while the net profit attributable to the parent company was 177 million yuan, down 3.98% year-on-year [1] - The large clinical business segment generated revenue of 512 million yuan in 2024, showing a robust growth of 41.19% year-on-year, indicating a strong support for the company's service sector in the next three years [2] - The self-developed new drug pipeline is progressing well, with key products entering various clinical phases, suggesting that 2025 may be a year of significant new drug transformations for the company [3] - The gross profit margin for 2024 was 50.18%, a decrease of 6.5 percentage points year-on-year, but is expected to stabilize as the market competition in pharmaceutical research stabilizes [4] - The operating cash flow for 2024 was 32 million yuan, a significant decrease, but the company is expected to recover quickly due to its strategic focus on serving large pharmaceutical clients [5] - The revenue forecast for 2025-2027 is set at 1.280 billion, 1.501 billion, and 1.756 billion yuan, with respective year-on-year growth rates of 18.73%, 17.19%, and 17.05% [6] Summary by Sections Financial Performance - In 2024, the company reported a revenue of 1.078 billion yuan and a net profit of 177 million yuan, with a notable decline in Q4 revenue to 162 million yuan, down 32.62% year-on-year [1] - The gross profit margin for 2024 was 50.18%, reflecting a decrease due to increased competition in the generic drug market and a higher proportion of lower-margin clinical service revenue [4] Growth Potential - The large clinical business segment is expected to continue its high growth trajectory, with a revenue increase of 41.19% in 2024 [2] - The self-developed new drug pipeline is advancing, with multiple products entering clinical trials, indicating potential for significant revenue contributions starting in 2025 [3] Profitability and Cash Flow - The company’s R&D expense ratio increased to 15.94% in 2024, driven by accelerated clinical progress of core self-developed pipelines [4] - Operating cash flow was reported at 32 million yuan, reflecting challenges in accounts receivable turnover, but a recovery is anticipated [5] Earnings Forecast - The company’s revenue projections for 2025-2027 are 1.280 billion, 1.501 billion, and 1.756 billion yuan, with net profits expected to grow to 179 million, 216 million, and 262 million yuan respectively [6]

❑ Q4 营收利润实现稳定增长 全年实现营收 10.44 亿元，同比增长 31.49%，实现归母净利润 3.62 亿元，同比 增长 22.22%，实现扣非归母净利润 3.41 亿元，同比增长 24.14%。全年毛利率达 89.63%，略微下降。费用率方面，销售、管理、研发费用率分别为 32.03%、 9.16%、19.79%，同比变化 -4.38、-0.23、-1.00 pct。全年经营性现金流为 4.73 亿 元，同比增长 36.95%。 分业务来看，软件产品使用授权营收达 8.94 亿元，同比增长 22.79%，毛利率达 99.69%，数据及行业解决方案营收达 0.98 亿元，同比增长 204.51%，运维服务营 业收入达 0.38 亿元，同比增长 38.50%。数据库一体机销售达 0.13 亿元，同比增 长 179.59%。 公司营收主要增长原因在于 证券研究报告 | 公司点评 | 软件开发 达梦数据(688692) 报告日期：2025 年 04 月 15 日 行业信创打开公司营收、利润增长新格局 ——达梦数据 2024 年度点评报告 投资要点 Q4 实现营收 4.15 亿元，同比增长 19.34%，实 ...

虹软科技(688088) 报告日期：2025 年 04 月 15 日 整体盈利能力大幅提升，商拍+AI 眼镜业务有望打开空间 ——虹软科技 2024 年报&2025 一季报点评 投资要点 ❑ 4 月 14 日，公司披露 2024 年报及 2025 年一季报。2024 年公司实现营业总收入 8.15 亿元（YoY +21.62%），实现归母净利润 1.77 亿元（YoY +99.67%），公司经 营效率大幅优化下盈利能力大幅提升。2025 年公司在智能手机、智能汽车业务 稳步增长的基础上，有望加速推进 AI 眼镜、AI 商拍业务的商业化落地，打开 新成长极。 证券研究报告 | 公司点评 | IT 服务Ⅱ ❑ 2024 年公司主营业务良好增长，盈利能力大幅提升 2024 年全年，公司实现营业总收入 8.15 亿元（YoY +21.62%），实现归母净利润 1.77 亿元（YoY +99.67%），扣非后归母净利润为 1.56 亿元（YoY+128.93%），盈 利能力大幅提升。公司全年整体毛利率为 90.43%（YoY +0.08pct），销售/管理/研 发费用率分别为 16.29%/10.49%/48.81%， ...

Investment Rating - The report maintains a "Positive" investment rating for the controlled nuclear fusion industry [5]. Core Insights - Controlled nuclear fusion is viewed as the ideal ultimate energy source for humanity, characterized by its abundant resources, cleanliness, safety, and efficiency [1][13]. - The industry is approaching a critical point, with engineering feasibility verification underway, and significant advancements expected in the near future [2][45]. - The global market for nuclear fusion equipment is projected to reach trillions, with a compound annual growth rate (CAGR) of approximately 23% from 2023 to 2035 [3][6]. Summary by Sections 1. Controlled Nuclear Fusion: The Ideal Ultimate Energy - Nuclear fusion involves the combination of two lighter atomic nuclei into a heavier nucleus, releasing substantial energy [1]. - Controlled nuclear fusion aims to harness this process under artificial conditions, making it a clean and sustainable energy source [1][13]. - The primary methods for achieving controlled fusion include magnetic confinement, inertial confinement, and gravitational confinement, with magnetic confinement being the focus of current research [1][19]. 2. Approaching Technical Singularity - The feasibility of nuclear fusion has been validated since the 1990s, and the industry is now in the engineering verification phase [2]. - If the engineering Q value exceeds 1, energy gain is possible; a Q value greater than 30 could lead to commercialization [2]. - Domestic and international efforts are catalyzing the industry, with significant milestones achieved recently, such as the "Circulation Three" project reaching high temperatures [2][45]. 3. Market Space Estimation - The global nuclear fusion equipment market is expected to see new additions worth trillions from 2031 to 2035, with a CAGR of about 23% [3][6]. - The domestic market for fusion equipment is projected to exceed hundreds of billions, with numerous projects planned and clear timelines established [2][3]. 4. Key Companies to Watch - The report highlights several key players in the midstream equipment sector, including: - Lianchuang Optoelectronics (high-temperature superconducting magnets) - Guoguang Electric (specialized microwave devices) - Antai Technology (divertors) [3][4]. - Upstream material suppliers such as Western Superconducting, Yongding Co., and Jingda Co. are also noted for their potential benefits from the industry [3].

证券研究报告 | 债券市场专题研究 | 债券研究 债券市场专题研究 报告日期：2025 年 04 月 15 日 关税 2.0 对产业债主体影响几何？ 核心观点 本文使用海外营收占比和美元存款/货币资金两种指标，并结合公开信息大致推测对美 出口较多的行业的产业主体对美出口敞口。从宏观行业和微观主体两个角度看，我们 认为关税政策对产业债信用风险的影响可控。 ❑ 我国对美出口情况概览 美国虽为我国第一大出口国，但我国对美贸易依赖度正逐渐下降，自从 2018 年贸易战 1.0 发生 以来，我国对美出口金额占比由 20%降至当前的 13%。不过，2018 年贸易战 1.0 爆发后关税清 单内商品对美出口显著下降，此次"全覆盖关税"作用下对美出口后续走势可能与此前类似。将 各类中国出口美国商品的 HS 编码转化为所属申万行业，对美出口金额较高的行业依次是电子、 轻工制造、电力设备、纺织服装、基础化工和汽车，该六大行业合计占对美出口总额的 80%以 上。 ❑ 如何衡量产业债发行主体出口敞口？ 美国对华加征关税将抬升出口成本，削弱企业盈利能力，出口型行业信用风险也可能随之上升。 但是，对美出口金额较高的行业产业债余额仅占全部 ...

证券研究报告 | 浙商早知道 报告日期：2025 年 04 月 15 日 浙商早知道 2025 年 04 月 15 日 ：王禾 执业证书编号：S1230512110001 ：021-80105901 ：wanghe@stocke.com.cn 市场总览 重要推荐 【浙商机械 邱世梁/王华君/何家恺/姬新悦】中大力德（002896）公司深度：精密减速器厚积薄发，卡位人形机器 人优质赛道——20250413 大势：4 月 14 日上证指数上涨 0.76%，沪深 300 上涨 0.23%，科创 50 上涨 0.25%，中证 1000 上涨 1.3%，创业板 指上涨 0.34%，恒生指数上涨 2.4%。 行业：4 月 14 日表现最好的行业分别是纺织服饰（+2.56%)、煤炭（+2.5%)、有色金属（+2.46%)、商贸零售（+2.37%)、 社会服务（+2.09%)，表现最差的行业分别是家用电器（-0.6%)、食品饮料（-0.36%)、房地产（+0.2%)、建筑材料 （+0.28%)、国防军工（+0.32%)。 资金：4 月 14 日全 A 总成交额为 13127 亿元，南下资金净流入 57.80 亿港元。 浙商早 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Insights - The report highlights the continuous upward development of the domestic innovative drug industry, with the company solidifying its leading position in clinical CRO and expecting sustained long-term performance growth due to international breakthroughs [1][11] - The company's 2024 revenue was reported at 6.603 billion RMB, a year-over-year decrease of 10.58%, primarily due to the impact of specific vaccine project bases and the cancellation of some domestic innovative drug clinical operation orders in H2 2024 [1][12] - The net profit attributable to the parent company for 2024 was 405 million RMB, reflecting a significant year-over-year decline of 79.99% [12] Summary by Sections Business Performance - Clinical trial technical service revenue for 2024 was 3.178 billion RMB, down 23.75% year-over-year, mainly due to the impact of specific vaccine projects and a decline in new order amounts for domestic innovative drug clinical operations [2] - Revenue from clinical trial-related and laboratory services was 3.296 billion RMB, showing a year-over-year increase of 5.61%, driven by strong demand and efficiency improvements [3] Profitability - The overall gross margin for 2024 was 33.95%, a decrease of 4.63 percentage points year-over-year, with clinical trial technical services gross margin at 29.56%, down 8.65 percentage points [4] - The report anticipates a gradual recovery in profitability, with expectations for gross margins to return to higher levels as order execution stabilizes [4] Order and Contract Insights - The company reported a net new contract amount of 8.42 billion RMB for 2024, a year-over-year increase of 7.3%, with a total backlog of contracts amounting to 15.78 billion RMB, up 12.1% year-over-year [11] - The overseas clinical operation business continues to grow rapidly, particularly in North America, with expectations for more high-quality MRCT orders [11] Financial Forecast - The report adjusts the earnings per share (EPS) forecast for 2025-2027 to 1.18, 1.40, and 1.70 RMB respectively, with a projected PE ratio of 38 times for 2025 [12]

证券研究报告 | 公司点评 | 种植业 投资要点 北大荒公告 2024 年业绩：24 年公司实现营收 53.39 亿元，同比+5.83%，归母净利润 10.87 亿元，同比+2.21%。单四季度公司实现营收 9.81 亿元，同比-7.89%，归母净利 润-2.60 亿元，亏损同比扩大 0.30 亿元。 ❑ 耕地发包业务延续增长，增收措施成效显著 1）耕地发包主业：公司积极采取机动地竞价、超规模阶梯收费等增收措施，实 现土地承包费收入稳健增长，24 年该业务营收 37.32 亿元，同比+8.7%。2）农产 品销售：24 年农产品销售实现营收 1.80 亿元，同比+11.60%，主要系粮食生产能 力与供给质量稳步提升。3）农资销售： 24 年农资业务实现营收 11.03 亿元，同 比-8.28%，主要系农资价格同比下滑。4）其他：公司工业、经贸业务均处于长 期停业状态，工业企业收入以出租资产为主，24 年实现营收 142 万元，同比+ 45 万元；经贸企业以清理应收和销售原有存货为主，24 年实现营收 4186 万元，同 比+ 4141 万元；房地产业务 24 年实现营收 126 万元，同比+5532 万元。 ❑ ...